Our Products

Contact

48-49 Russell Square, London, WC1B 4JP UK

T: +44 (0)203 0084416

E: info@valirx.com

Val 101

GeneICE technology exploits the fact that gene expression is controlled by small chemical changes to DNA sequences and to the proteins that associate with them. In particular, acetylation of basic lysine residues in histones – the proteins that DNA binds to form the compact structure of chromatin and, thus, chromosomes – causes the DNA to "unwind" enough to allow gene expression, whereas histone deacetylation causes the chromatin to condense and prevents expression.

Cancer is caused by aberrant gene expression. GeneICE technology "turns off" genes that are over-expressed in cancer by mimicking the natural process of histone deacetylation. This involves a class of enzymes known as histone deacetylases (HDAC). GeneICE compounds consist of a combination of peptides; one binds selectively to the target gene (Bcl-2) and another that recruits the patient's HDAC enzymes to the gene, silencing it by histone deacetylation. Mis-expression of Bcl-2 has been associated with most cancers and it is currently thought that Bcl-2 is over-expressed in up to 80% of breast cancers, 90% of prostate cancers and 80% of leukaemias. As such the potential market for GeneICE compounds is very large.

The company's first GeneICE candidate molecule is currently on track to enter Phase I clinical trials for androgen independent prostate cancer in 2013.

test tubes